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Purpose: These studies evaluate the relative bio-
availability of crushed apixaban tablets and the effect
of food on apixaban pharmacokinetic properties.
Methods: An open-label, randomized, crossover
study in 33 healthy adults compared the bioavailabil-
ity of 2  5-mg apixaban tablets administered whole
(reference), crushed and suspended in 30 mL of water,
and crushed and mixed with 30 g of applesauce. A
second open-label, randomized, crossover study in 22
healthy adults compared apixaban 1  5-mg tablet
administered when fasted (reference) or immediately
after consumption of a high-fat, high-calorie meal.
Point estimates and 90% CIs for geometric mean
ratios were generated for Cmax, AUC0–1, and AUC0–t.
Findings: Cmax and AUC met bioequivalence cri-
teria for crushed tablets in water. Cmax and AUC
decreased by 21.1% and 16.4%, respectively, with the
lower bound of the CIs falling below the bioequiva-
lence criteria for crushed tablets with applesauce.
Similarly, administration of whole tablets with a
high-fat, high-calorie meal reduced apixaban Cmax
and AUC by 14.9% and 20.1%, respectively. The
exposure reductions in both studies were considered
not clinically signiﬁcant.
Implications: Apixaban tablets can be administered
crushed or whole, with or without food. The results of
these alternative methods of administration support
their use in patients who have difﬁculty swallowing
tablets. ClinicalTrials.gov identiﬁers: NCT02101112
and NCT01437839. (Clin Ther. 2016;38:1674–1685)
& 2016 The Authors. Published by Elsevier HS
Journals, Inc.
Key words: apixaban, bioavailability, crushed tab-
let, food effect, formulation, stability.1674INTRODUCTION
The oral, selective, direct, reversible factor Xa inhib-
itor apixaban1,2 is approved in the European Union,
United States, and many other countries to reduce the
risk of stroke and systemic embolism in patients with
nonvalvular atrial ﬁbrillation,3,4 for thromboprophy-
laxis after elective hip or knee replacement surgery,5–7
for the treatment of deep vein thrombosis or pulmo-
nary embolism,8 and to reduce the risk of recur-
rent venous thromboembolism after an initial
thromboembolic event.9 Apixaban is an immediate-
release tablet formulation with rapid dissolution (at
least 80% dissolved within 30 minutes) and pH-
independent aqueous solubility. Apixaban has predict-
able pharmacokinetic (PK) properties, and exposure
is dose proportional for the approved dose range of
2.5 to 10 mg.10–16 The bioavailability of apixaban is
approximately 50%,17 and it is absorbed primarily in
the upper gastrointestinal (GI) tract, proximal to the
colon.18 Peak apixaban plasma concentration is
reached approximately 3 hours after oral admin-
istration in healthy adults, with a mean elimination
t½ of approximately 12 hours.
12 Elimination occurs
via multiple pathways, including metabolism, renal
elimination of unchanged drug, and excretion into the
intestinal tract.19,20 In addition to having a pharma-
cologic proﬁle consistent with twice-daily dosing,Volume 38 Number 7
Y. Song et al.there is limited potential for drug-drug or drug-food
interactions.16,21–27
Certain patients, such as elderly individuals, young
children, and some hospitalized patients, may be unable
to swallow solid dosage forms. Pediatric patients
o6 years of age may have difﬁculty swallowing adult
dosage forms, and dysphagia is also a common potential
complication of treatment in elderly patients.28–35 Patients
with difﬁculty swallowing medication are more likely to
delay or skip taking their medications entirely or seek
alternate methods of administration. As a consequence,
dysphagia is associated with a higher risk of medication
errors.36 In these patients, in the absence of alternative
formulations, mixing capsule contents or crushed tablets
with semisolid foods or liquids is a common practice.
However, extemporary manipulations of solid oral dose
forms can alter the PK properties of the drug, and in
some cases, relative bioavailability may be signiﬁcantly
affected. For example, the oral bioavailability of
dabigatran etexilate mesylate increases by 75% when
the pellets are taken without the capsule shell compared
with the intact capsule formulation.37
Apixaban is classiﬁed as a Biopharmaceutics Clas-
siﬁcation System Class III compound (high solubility/
low permeability)38 and is nonionizable1,39; thus,
changes in pH do not affect the aqueous solubility
of apixaban. Apixaban is available as small 2.5- and
5-mg ﬁlm-coated tablets (the length of the 5-mg tablet
is 9.73 mm; Bristol-Myers Squibb, data on ﬁle), which
are expected to be relatively easy to swallow. How-
ever, there may still be patients who would beneﬁt
from apixaban but have difﬁculty swallowing an
intact tablet. Therefore, a study evaluating the relative
bioavailability of apixaban tablets after being crushed
and mixed with different media was conducted.
In addition to the dosage form and patient-speciﬁc
factors, such as weight, age, and renal function,
various factors associated with how medication is
administered can also affect PK properties; these
factors include interactions with concomitant medica-
tions or food. For example, warfarin is known to have
multiple drug-drug interactions and is susceptible to
interaction with dietary components.40 Several studies
have identiﬁed an effect of food on the PK properties
of the factor Xa inhibitor rivaroxaban when
administered after a high-carbohydrate or high-fat
meal,41 and rivaroxaban prescribing information
recommends that doses Z15 mg be taken with food,
whereas lower doses can be taken with or withoutJuly 2016food.42 A previous dedicated food effect study of
apixaban found that the 90% CIs for both Cmax and
AUC were entirely within the predetermined 80% to
125% equivalence interval, therefore indicating no
clinically signiﬁcant effect of food on apixaban PK
properties.16 An additional food effect study was
conducted using the marketed apixaban tablet
formulation.
We report the results of the crushed tablet relative
bioavailability study (study 1) and the commercial
tablet food effect study (study 2). Furthermore, to
support the administration of apixaban crushed tab-
lets in liquid media or a soft-food vehicle, an assess-
ment of apixaban stability was conducted to ensure
that crushed tablets are stable in water, 5% dextrose
in water (D5W), apple juice, and applesauce.PARTICIPANTS AND METHODS
Study Population
Studies 1 and 2 included healthy adults, deﬁned as
those having no clinically signiﬁcant deviation from
normal in medical history, physical examination,
ECGs, and clinical laboratory determinations and
women of childbearing potential who had a negative
serum pregnancy test result within 24 hours before
starting the investigational product. In addition, par-
ticipants in study 1 had to be 18 to 45 years of age,
with a body mass index of 18 to 30 kg/m2. Partic-
ipants in study 2 had to be 21 to 45 years of age, with
a body mass index of 17.5 to 30.5 kg/m2. All
participants were required to provide written in-
formed consent before participation.
Individuals were excluded from either study for any
history or evidence of abnormal bleeding, intracranial
hemorrhage, or coagulation disorders, any GI surgery,
or other conditions or comedications that could affect
absorption of study drug, prescription drugs, over-the-
counter medications or herbal preparations within 2
to 4 weeks of study commencement, or current or
recent (within 3 months) GI disease, including, but not
limited to, dyspepsia, GI ulcers, esophageal or gastric
varices, hemorrhoids, or any known history of coex-
isting disease within the previous 6 months that may
be associated with an elevated risk of bleeding.
Study Design
The primary objectives of study 1 were to assess the
bioavailability of apixaban crushed tablets suspended1675
Clinical Therapeuticsin water or mixed with applesauce relative to apix-
aban whole tablets, all administered orally in healthy
adults. Secondary objectives were to assess the safety
and tolerability of apixaban and to assess the PK
properties of apixaban crushed tablets when sus-
pended in water or mixed with applesauce. The
primary objective of study 2 was to evaluate the effect
of food on apixaban PK properties after administra-
tion of single-dose apixaban commercial formulation
tablets in healthy adults. The protocol for each study
was approved by the independent review board of the
site where the study took place, and both studies
complied with all local regulations, the Declaration of
Helsinki, and the International Conference on Har-
monisation guidelines on Good Clinical Practice.
Study 1
Study 1 (NCT02101112) was an open-label,
randomized, 3-treatment crossover study in healthy
adults. Participants were admitted to the clinical
facility on day 1 and remained at the clinical facility
for the duration of the study. On day 1, participants
were randomly assigned to 1 of 6 treatment sequences.Table I. Study treatments.
Crushed tablet study
Treatment A
(reference)
Apixaban tablets (2  5 mg) were
of water.
Treatment B Apixaban tablets (2  5 mg) were g
ﬁne powder) using a mortar and
of water, and the rinse solution u
with which the suspension was a
with 30 mL of water, also admin
additional 180 mL of water.
Treatment C Apixaban tablets (2  5 mg) were g
ﬁne powder) using a mortar and
applesauce in a dosing cup. The
and both the applesauce mixture
Approximately 30 mL of water wa
with the rinse solution administer
180 mL of water.
Food effect study
Treatment A
(reference)
Apixaban (1  5-mg tablet) was ad
Treatment B Apixaban (1  5-mg tablet) was adm
high-fat, high-calorie breakfast.
1676All 3 treatments were composed of 10 mg of apixaban
and 240 mL of water, with treatment C including an
additional 30 g of applesauce (Table I). For each
treatment period, apixaban was dosed immediately
after a 10-hour overnight fast. Participants were not
permitted to drink any additional water within 1 hour
before or after dosing, with a 4-day washout period
between treatments. A 10-mg (2  5-mg tablets) dose
was selected because it is the highest approved dose of
apixaban.
Study 2
Study 2 (NCT01437839) was an open-label,
randomized, 2-treatment crossover study in healthy
adults. Participants were admitted to the clinical
facility on day 1 and remained at the clinical facility
for the duration of the study. On day 1, participants
were randomly assigned to 1 of 2 treatments and
received the alternate treatment during the second
study period. Both treatments were composed of 5 mg
of apixaban and 240 mL of water, administered while
the participant was in a fed or fasted state (Table I).
A 5-mg dose was selected because it is the highestadministered whole with approximately 240 mL
ently crushed into a coarse particulate form (ie, not a
pestle, with the mortar and pestle rinsed with 30 mL
sed to suspend the crushed tablet in a dosing cup,
dministered orally. The dosing cup was then rinsed
istered orally, and the subject was provided with an
ently crushed into a coarse particulate form (ie, not a
pestle and thoroughly mixed with 30 g of Mott’s
mortar and pestle were rinsed with 30 mL of water,
and rinse solution were administered orally.
s used to rinse the rinse cup, spoon, and dosing cup,
ed orally and the subject provided with an additional
ministered with approximately 240 mL of water.
inistered with approximately 240 mL of water after a
Volume 38 Number 7
Y. Song et al.approved apixaban tablet strength and was the high-
est approved dose at the time of study. For each
treatment period, apixaban was dosed immediately
after a 10-hour overnight fast or, in the case of the
fed-state treatment, within 5 minutes of completing a
high-fat, high-calorie breakfast (consisting of 2 fried
eggs [large], 80 g of turkey bacon, 2 slices of white
bread, 80 g of potato for hash browns, 45 g of butter
[for cooking], and 240 mL of whole milk consumed
within 30 minutes; total calories, 979 kcal, with
15%, 60%, and 25% from protein, fat, and carbo-
hydrate, respectively) after a 10-hour fast. Partici-
pants were not permitted to eat or drink any
additional water within 1 hour before or after dosing
or to eat any additional food within the 4 hours after
dosing, with a 5-day washout period between
treatments.PK Assessments
Blood samples (2.7 mL in 3.2% sodium citrate) for
assessment of apixaban plasma concentrations were
collected by venipuncture or indwelling catheter be-
fore dosing (0 hour) and at 0.25, 0.5, 1, 2, 3, 4, 5, 6,
9, 12, 24, 36, 48, 60, and 72 hours after dosing in
study 1 and before dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 9,
12, 24, 48, 60, and 72 hours after dosing in study 2.
For both studies, apixaban concentration in human
plasma was assayed using a validated liquid chroma-
tography atmospheric pressure ionization tandem
mass spectrometry method with a lower limit of
quantiﬁcation of 1 ng/mL during the period of known
analyte stability (Intertek Pharmaceutical Services, El
Dorado Hills, California).43
Apixaban PK parameters derived from plasma
concentration–time proﬁles of apixaban included
Cmax, AUC0–1, AUC0–t, Tmax, and t1/2, using Phoenix
WinNonlin, version 6.2.1 (Pharsight Corporation,
St Louis, Missouri), in study 1 and using a Pﬁzer
internally developed and validated software system,
eNCA (electronic noncompartmental analysis), ver-
sion 2.2.3 (Pﬁzer, New York, New York), in study 2.
Point estimates and 90% CIs for geometric mean
ratios were generated for comparison of Cmax, AUC1,
and AUC0–t between each treatment and the reference
treatment. In study 1, the relative bioavailability,
deﬁned as the ratio of test AUC1 to reference
AUC0–1, was also derived. All statistical analyses
were performed using SAS software, version 9.2July 2016(study 2) or 9.3 (Study 1) (SAS Institute, Cary,
North Carolina).Safety Profile Assessments
Safety proﬁle assessments for both studies were
based on adverse event (AE) reports and results of
vital sign measurements, physical examinations, 12-
lead ECGs, and clinical laboratory tests performed at
baseline and selected times throughout the study.Sample Size Calculations
For study 1, the hypotheses were as follows: (1)
there is no difference between the oral bioavailabilities
of apixaban crushed tablets suspended in water relative
to apixaban whole tablets, and (2) there is no difference
between the oral bioavailabilities of apixaban crushed
tablets mixed with applesauce relative to apixaban
whole tablets. Similarity of bioavailability would be
concluded if the 90% CIs for the ratio of geometric
means of apixaban crushed tablets suspended in water
or mixed with applesauce relative to apixaban whole
tablets were wholly contained within 80% to 125% for
Cmax and AUC. If there was no difference between the
bioavailability of apixaban crushed tablets suspended
in water relative to apixaban whole tablets, then data
from 28 participants would provide approximately
98%, 99%, and 99% power to conclude similar
bioavailability for Cmax, AUC0–1, and AUC0–t, respec-
tively. The overall power was 96% and 92% for both
hypotheses, respectively. These calculations use the
approach described by Diletti et al44 and assume
Cmax and AUC are log-normally distributed with
intraindividual SD of 0.20 for ln(Cmax) and 0.19 for
ln(AUC) (Bristol-Myers Squibb, data on ﬁle, 2008). To
allow for possible dropouts, a total of 33 participants
were randomly assigned to treatment.
For study 2, the hypothesis was that there was no
difference between the oral bioavailability of apixaban
when administered in a fed or fasted state. A sample
size of 20 participants would provide 90% CIs for
apixaban Cmax and AUC for the difference between
treatments of 88% to 113% and 92% to 109%,
respectively, with 90% coverage probability. These
calculations were based on estimates of intraindivid-
ual SD of 0.186 and 0.129 for ln(Cmax) and ln(AUC),
respectively (Bristol-Myers Squibb, data on ﬁle, 2007).
To allow for possible dropouts, 22 participants were
randomly assigned to treatment.1677
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Three different doses of apixaban (2.5 mg, 5 mg,
and 2  5 mg) were tested for stability when
suspended in water, D5W, or apple juice (Mott’s)
and when mixed with applesauce (Mott’s). Tablets
were gently crushed in a mortar and pestle and
suspended in water, D5W, or apple juice or mixed
with applesauce. The suspensions/mixtures were ana-
lyzed for potency and impurities at the initial time
point (0 hour) and at 4 hours after incubation at 301C
and 75% relative humidity under normal room
lighting.RESULTS
Demographic Characteristics and Disposition of
the Study Participants
A summary of demographic characteristics at base-
line for all individuals randomly assigned to treatment
is given in Table II for both studies. Study 1 was
conducted at the Covance Clinical Research Unit Inc
(Daytona Beach, Florida). A total of 33 healthy adults,
comprising 21 white (64%), 8 black/African American
(24%), 1 American Indian/Native Alaskan, and 3
other, were randomly assigned to treatment. A total
of 31 of 33 individuals completed the study, with 1
individual (3%) withdrawn from the study because ofTable II. Demographic characteristics of the
study patients.
Characteristic
Crushed tablet
study (n ¼ 33)
Food effect
study (n ¼ 22)
Age, y
Mean (SD) 32.3 (7.4) 31.2 (6.2)
Range 20-45 21-43
Sex, No. (%)
Male 26 (79) 18 (82)
Female 7 (21) 4 (18)
BMI, kg/m2
Mean (SD) 26.1 (2.2) 23.6 (2.6)
Range 20.3-29.9 19.1-29.1
Weight, kg
Mean (SD) 77.4 (7.9) 69.2 (10.1)
Range 59.2-89.7 50.1-86.6
BMI ¼ body mass index.
1678AEs and 1 (3%) who withdrew consent to participate
during the third treatment period. Study 2 was
conducted at the Pﬁzer Clinical Research Unit in
Singapore. All participants who enrolled in the study
were Asian, and all but 4 participants were male. A
total of 21 of 22 participants completed the study,
with 1 (4.5%) withdrawing consent to participate
during the second treatment period.
PK Properties
In study 1, the relative bioavailability of crushed
tablets suspended in water or mixed with applesauce
was 103% and 83.6%, respectively, compared with
whole tablets (Table III). Apixaban mean Cmax and
AUC were similar when administered as whole tablets
or crushed tablets suspended in water, with Cmax,
AUC0–t, and AUC0–1 values meeting the predeﬁned
80% to 125% bioequivalence criteria (Figure 1 and
Table IV). When apixaban was administered as
crushed tablets mixed with applesauce, apixaban
Cmax and AUC1 were 21% and 16% lower,
respectively, than the corresponding values observed
after administration of whole tablets, with the lower
bound of the CIs for Cmax, AUC0–t, and AUC0–1
falling outside the predetermined bioequivalence
criteria (Figure 1 and Table IV). The median Tmax of
apixaban was 2 hours, regardless of the route of
administration. The t1/2 was also unaffected by
administration method, ranging from 12.2 to 12.5
hours (Figure 1 and Table III).
For study 2, when apixaban was administered
under fed conditions, apixaban Cmax and AUC0–1
were 15% and 20% lower, respectively, than the
corresponding values observed after administration
of apixaban under fasted conditions (Table IV). The
median Tmax of apixaban was 2 hours when
administered in a fed state versus 3 hours when
administered after an overnight fast. Mean t1/2
values for fed and fasted conditions were similar for
both treatments (10.7 and 9.87 hours after fed and
fasted apixaban administration, respectively) (Figure 2
and Table III).
Safety Profile
For study 1, there were no treatment-related
serious AEs or bleeding-related AEs. AEs, all of
which were considered mild, were reported for 3
individuals (9%). One participant was withdrawn
from the study because of AEs (mild pruritus andVolume 38 Number 7
Table III. Statistical analysis of key apixaban plasma pharmacokinetic parameters.
Study
Cmax, GM
(%CV),
ng/mL
AUC0–1,
GM (%CV),
ng  h/mL
AUC0–t,
GM (%CV),
ng  h/mL
Tmax, Median
(Range), h
t1/2, Mean
(SD), h
Frel, GM
(CV%), %
Crushed tablet study (n ¼ 33)
(A) 2  5-mg apixaban
tablets (n ¼ 32)
233 (27) 2443 (27) 2406 (27) 2.00 (1.00–5.00) 12.4 (5.4) –
(B) 2  5-mg apixaban
tablets crushed and
suspended in 30 mL
of water (n ¼ 33)
249 (23) 2528 (22) 2488 (22) 2.00 (0.58–4.00) 12.2 (5.2) 103* (24)
(C) 2  5-mg apixaban
tablets crushed and
mixed with 30 g of
applesauce (n¼32)
185 (23) 2044 (22) 2003 (23) 2.00 (1.00–4.00) 12.5 (5.1) 83.6 (20)
Food effect study (n ¼ 22)
(A) 1  5-mg apixaban
tablet administered in
a fasted state (n ¼ 22)
121.3 (28) 1229 (22) 1200 (23) 3.00 (1.00–6.00) 9.87 (2.35) –
(B) 1  5-mg apixaban
tablet administered
following a high-fat,
high-calorie meal
(n ¼ 22)
103.2 (20) 971.6 (21) 937.6 (22) 2.00 (0.917–4.02) 10.7 (2.97)† –
Frel ¼ relative bioavailability; GM ¼ geometric mean.
*n ¼ 32.
†n ¼ 21.
Y. Song et al.rash) considered by the investigator to be related to
the study drug. These AEs were resolved with oral
antihistamine and corticosteroid treatment. All other
AEs were considered to be unrelated to the study
drug. There were no clinically meaningful abnormal-
ities in clinical laboratory values, vital signs, ECGs,
or physical examinations.
For study 2, there were no deaths, serious AEs, or
withdrawals from the study due to AEs, with all
reported AEs categorized as mild and resolved with-
out treatment. Two participants (9%) experienced
treatment-related AEs under fasted conditions com-
pared with 3 participants (14%) under fed condi-
tions. The only treatment-related AE that occurred in
41 participant was headache, which was reportedJuly 2016for 2 participants under fasted conditions. There
were no clinically meaningful abnormalities in clin-
ical laboratory values, vital signs, ECGs, or physical
examinations.Stability Assessment
Apixaban was stable for 4 hours when the crushed
tablet, equal to 2.5, 5, and 10 mg of apixaban, was
suspended in water, D5W, or apple juice or when mixed
with applesauce and incubated at 301C/75% relative
humidity under room lighting (Supplemental Table I).
There was at least 95.8% of the stated label claim dose
present after the 4-hour incubation period for all doses
and media tested.1679
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Figure 1. Mean apixaban plasma concentration–time profiles after administration of a single 10-mg dose of
oral apixaban. Error bars indicate þ1 SD. Inset shows the semilog plot of the same profiles.
Clinical TherapeuticsDISCUSSION
In study 1, administration of apixaban as crushed
tablets suspended in water met the bioequivalence
criteria, with the geometric mean ratios for Cmax and
AUC close to unity and the 90% CIs contained within
the 0.8 to 1.25 boundary, indicating that administra-
tion of the tablet in this manner does not affect the
extent of apixaban absorption. This ﬁnding is con-
sistent with previous studies reporting that there is
comparable bioavailability between apixaban tablets
and an apixaban oral solution and comparable bio-
availability between an apixaban oral solution and
crushed tablets suspended in D5W and administered
through a nasogastric tube.45 A limitation of this
study and of the previous experience is that tablets
were crushed using a mortar and pestle and a rinse
procedure was followed. In clinical practice, methods
for crushing tablets may vary. As with any
extemporaneous compounding, care is needed to
avoid loss of drug and to ensure the full dose of the
drug is administered. As long as such care is taken, the
results of this study, along with previous study results,
indicate that crushed apixaban tablets suspended in
ﬂuids such as water is an acceptable method of
apixaban administration.1680Unlike administration of crushed tablets suspended
in water, administration of crushed apixaban tablets
mixed in applesauce did not result in equivalent
exposure to whole apixaban tablets after fasted ad-
ministration. As we have found, apixaban is stable in
applesauce for at least 4 hours; therefore, loss of drug
due to instability in applesauce is not a factor because
the entire dose was consumed within the stability
window. Applesauce or apple juice can inhibit human
organic anion transporters46; however, apixaban is not
a substrate for organic anion transporter (Bristol-
Myers Squibb, data on ﬁle). Apixaban is a substrate
of P-glycoprotein and breast cancer resistance protein,
2 efﬂux transporters located in the intestine, although
consumption of applesauce or apple juice is not known
to inﬂuence P-glycoprotein or breast cancer resistance
protein function. In addition, these transporters are
efﬂux transporters, and inhibiting their function would
tend to increase bioavailability.47 Therefore, the
reduced apixaban exposure in the presence of
applesauce is not likely to be transporter mediated.
In contrast, the food effect ﬁndings reported here
indicate that apixaban exposure was lower after
coadministration with food, whereas the previous
food effect study found a slightly higher apixabanVolume 38 Number 7
Table IV. Statistical analysis of apixaban Cmax, AUC0–1, and AUC0–t
Treatment
Cmax, AGM,
ng/mL
AUC0–1, AGM,
ng  h/mL
AUC0–t, AGM,
(ng  h/mL)
Crushed tablet study (n ¼ 33)
(A) 2  5-mg apixaban tablets (n ¼ 32) 236 2461 2423
(B) 2  5-mg apixaban tablets crushed and
suspended in 30 mL of water (n ¼ 33)
249 2528 2488
(C) 2  5-mg apixaban tablets crushed and mixed
with 30 g of applesauce (n ¼ 32)
186 2055 2015
Comparison of crushed tablets suspended in water vs
whole tablets, adjusted GMR (90% CI)
1.05
(0.994–1.118)
1.03
(0.981–1.076)
1.03
(0.981–1.075)
Comparison of crushed tablets mixed with applesauce
vs whole tablets, adjusted GMR (90% CI)
0.788
(0.741–0.839)
0.835
(0.797–0.875)
0.832
(0.794–0.871)
Food effect study (n ¼ 22)
(A) 1  5-mg apixaban tablet administered in a fasted
state
121.3 1229 1200
(B) 1  5-mg apixaban tablet administered after a
high-fat, high-calorie meal
103.2 982.3* 948.2*
Comparison of fed vs fasted, adjusted GMR (90% CI) 0.851
(0.793–0.914)
0.799
(0.752–0.850)
0.790
(0.741–0.843)
AGM ¼ adjusted geometric mean; GMR ¼ geometric mean ratio.
*n ¼ 21.
Y. Song et al.exposure (10% higher for Cmax and 4% higher for
AUC0–1) in the presence of food.
16 The ﬁndings of
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oral apixaban. Error bars indicate 1 SD. Inset
July 2016consistent, however, with ﬁndings after administration
of an apixaban oral solution with infant formula or
Boost Pluss (Nestlé, Vevey, Switzerland) (19%–32%0 12 24 36 48 60 72
36 48 60 72
Time (h)
e (h)
ofiles after administration of a single 5-mg dose of
shows the semilog plot of the same profiles.
1681
Clinical Therapeuticsdecrease in Cmax and 8%–19% decrease in
AUC0–1).
45 The difference between the effect of
food in the original food effect study and these more
recent evaluations is unclear. Nonetheless, the Phase II
tablet formulation used in the original food effect
study has similar dissolution characteristics to that of
the ﬁnal, commercial formulation and met the in vitro
dissolution criteria for equivalence (Bristol-Myers
Squibb, data on ﬁle, 2006). In addition, comparable
bioavailability between the formulations was found in
a relative bioavailability study (Bristol-Myers Squibb,
data on ﬁle, 2007).
In general, a negative food effect is most likely to
occur for Biopharmaceutics Classiﬁcation System
Class III drugs, such as apixaban, particularly if food
interacts with drug absorption.48,49 Different mecha-
nisms have been postulated. For example, an increase
in viscosity of the dissolution ﬂuid particularly affects
the absorption of Biopharmaceutics Classiﬁcation
System Class III compounds that have preferential
absorption in the upper GI tract if the drug re-
lease from the dosage form is delayed.50 How-
ever, apixaban exposure is reduced regardless of
formulation in the presence of food (including high-
fat, high-calorie meal, infant formula, nutritional
drink, and applesauce); therefore, the viscosity of the
intestinal content may not be the explanation. It is
possible that the decrease in exposure is due to change
in GI transit time with food consumption, therefore
decreasing the fraction of the dose available for
absorption.51 In the study by Penrod et al,52
persistent subtherapeutic prothrombin times were
observed in 2 case studies in which warfarin was
administered through a nasogastric tube with a
nutritional supplement. The authors suggested that
this could be attributable to binding between warfarin
and the nutritional supplement components. In a
follow-up in vitro experiment in which binding be-
tween Boost Plus and apixaban was measured, similar
binding was observed for apixaban (Bristol-Myers
Squibb, data on ﬁle, 2015). Therefore, nonspeciﬁc
binding to certain nutritional supplement components
may be one of the explanations for reduced apixaban
exposure in the presence of Boost Plus and a high-
fat meal.
It is evident that the effect of food, if any, on
apixaban exposure is minimal because the effect of
food on apixaban exposure across these studies was a
decrease of r20%. Approximately 35,600 patients1682have been treated with apixaban in 15 completed
Phase II and Phase III clinical trials spanning several
different patient populations, with apixaban adminis-
tered twice daily without regard to meals in all those
studies. Considering the favorable beneﬁt-risk proﬁle
observed in the Phase III studies,3–9 any apparent
effect of food on apixaban exposure does not have a
clinically relevant effect; thus, apixaban is adminis-
tered with or without food in clinical practice. There-
fore, given the modest effect of crushing and mixing
apixaban tablets with applesauce on apixaban expo-
sure, this method of administration may represent a
viable alternative for patients who have difﬁculty
swallowing. Apixaban was generally well tolerated
in both of the studies presented here, and there were
no unexpected tolerability issues raised regardless of
treatment received.CONCLUSION
Apixaban bioavailability was comparable between
whole tablets and crushed tablets suspended in water;
these results support crushed tablets suspended in
water as a viable method of administration in patients
who are unable to swallow solid dosage forms.
Although administration of crushed apixaban tablets
mixed with applesauce and administration of apix-
aban tablets with a high-fat, high-calorie meal resulted
in a somewhat decreased apixaban exposure, the
effect was small and considered not clinically relevant.
Overall, these results support the use of crushed
tablets as an appropriate method of apixaban admin-
istration in patients who have difﬁculty swallowing
whole tablets and indicate that apixaban can be taken
with or without food.FUNDING SOURCES
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Table SI.Supplementary Table I. Apixaban Crushed Tablet
Stability Assessment in
Selected Media
% Label Claim at Stability
Time Point
Tablet Medium T ¼ 0 h T ¼ 4 h*
2.5 mg Water 98.0 99.2
D5W 95.2 98.0
Applesauce 97.6 99.2
Apple juice 100.0 96.4
5 mg Water 97.8 97.0
D5W 99.0 97.4
Applesauce 101.4 101.6
Apple juice 97.6 95.8
25 mg Water 97.5 97.9
D5W 100.0 98.1
Applesauce 99.7 97.3
Apple juice 97.1 97.1
*Apixaban crushed tablets were incubated in selected
media for 4 hours at 301C and 75% relative humidity.1685.e1 Volume 38 Number 7
